Feasibility and early experience of a novel multidisciplinary alcohol-associated liver disease clinic

被引:39
|
作者
Mellinger, Jessica L. [1 ]
Winder, Gerald Scott [2 ,7 ]
Fernandez, Anne C. [2 ,3 ]
Klevering, Kristin [3 ,4 ]
Johnson, Amanda [1 ]
Asefah, Haila [1 ]
Figueroa, Mary [5 ]
Buchanan, Jack [6 ]
Blow, Fred [2 ,3 ]
Lok, Anna S. F. [1 ]
机构
[1] Michigan Med, Dept Internal Med, Ann Arbor, MI USA
[2] Michigan Med, Dept Psychiat, Ann Arbor, MI USA
[3] Univ Michigan, Addict Treatment Serv, Michigan Med, Ann Arbor, MI 48109 USA
[4] Michigan Med, Dept Social Work, Ann Arbor, MI USA
[5] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA
[6] Univ Michigan, Med Sch, Ann Arbor, MI USA
[7] Michigan Med, Dept Surg, Ann Arbor, MI USA
关键词
Alcoholic cirrhosis; Psychiatry; Addiction; Alcohol use disorder; Quality; VALIDATION; DISORDER;
D O I
10.1016/j.jsat.2021.108396
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Alcohol cessation improves mortality in alcohol-associated liver disease (ALD), but access to treatment is limited. To address this gap, implementation and early feasibility and outcomes of a multidisciplinary ALD clinic are described. Methods: The clinic comprised a hepatologist, psychiatrist, psychologist, nurse, and social worker. Patients included those with alcohol-associated cirrhosis or acute alcoholic hepatitis who were not in the transplant evaluation process, who had less than 6 months' sobriety and willingness to engage in alcohol use treatment. Psychosocial metrics in addition to routine hepatic function labs were collected. Treatment plans were tailored based on patient preferences and needs after multidisciplinary discussion. Results: 89 patients were referred from both inpatient and outpatient settings, with 51 seen during the initial year. 38 remained active in clinic (4 died, 6 discharged, 3 moved to transplant clinic). 55% were women, 88% were white, 61% had private insurance. 49% had alcoholic hepatitis. 71% were decompensated. 80% had severe alcohol use disorder (AUD) and 84% had at least 1 comorbid psychiatric or substance use disorder. 63% chose one-on-one AUD treatment, 57% were prescribed relapse prevention medications. Mean MELD-Na score improved from baseline of 14 (SD 6.6) to 11.3 at 6 months (p=0.01). Hospital utilization significantly declined when comparing 6 months before to 6 months after initial visit (emergency department visits: 0.51 to 0.20 per person-month; inpatient admission: 0.34 to 0.14 per person-month; (beta=-0.89, 95% CI-1.18 to -0.60). Conclusions: A multidisciplinary ALD clinic was feasible with encouraging early outcomes. Further research should explore ways to expand this model and increase clinic capacity.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] The Experience of the Alcohol-Associated Liver Disease Organ Transplant Recipient Following Liver Transplantation
    Greenberg, Cindy
    Roush, Karen
    NURSING RESEARCH, 2024, 73 (03) : E117 - E117
  • [22] Alcohol Use Disorder and Alcohol-Associated Liver Disease
    Ramkissoon, Resham
    Shah, Vijay H.
    ALCOHOL RESEARCH-CURRENT REVIEWS, 2022, 42 (01):
  • [23] Liver Iron Loading in Alcohol-Associated Liver Disease
    Ali, Najma
    Ferrao, Kevin
    Mehta, Kosha J.
    AMERICAN JOURNAL OF PATHOLOGY, 2023, 193 (10): : 1427 - 1439
  • [24] Outcomes from early liver transplantation for alcohol-associated liver disease at a single center
    Meinders, A.
    Connor, A. A.
    Patel, K.
    Ontiveros, J.
    Nottage, D. L.
    Brombosz, E. W.
    Moore, L. W.
    Simon, C. J.
    Cheah, Y. L.
    Hobeika, M.
    Mobley, C. M.
    Saharia, A.
    Basra, T.
    Kodali, S.
    Victor, D. W., III
    Gaber, A. O.
    Ghobrial, R. M.
    LIVER TRANSPLANTATION, 2024, 30 : 52 - 52
  • [25] Transplant Center Attitudes Toward Early Liver Transplant for Alcohol-associated Liver Disease
    Mitchell, Jonathan
    Herrick-Reynolds, Kayleigh
    Motter, Jennifer D.
    Teles, Mayan
    Kates, Olivia
    Sung, Hannah
    Chen, Po-Hung
    King, Elizabeth
    Cameron, Andrew
    TRANSPLANTATION DIRECT, 2023, 9 (09): : E1532
  • [26] The lymphatic system in alcohol-associated liver disease
    Kondo, Reiichiro
    Iwakiri, Yasuko
    CLINICAL AND MOLECULAR HEPATOLOGY, 2020, 26 (04) : 633 - 638
  • [27] Advances in the management of alcohol-associated liver disease
    Anouti, Ahmad
    Kerr, Thomas A.
    Mitchell, Mack C.
    Cotter, Thomas G.
    GASTROENTEROLOGY REPORT, 2024, 12
  • [28] Transplant Center Attitudes Towards Early Liver Transplantation for Alcohol-associated Liver Disease
    Mitchell, Jonathan
    Motter, Jennifer
    Teles, Mayan
    Herrick-Reynolds, Kayleigh
    Sung, Hannah
    Chen, Po-Hung
    King, Elizabeth
    Cameron, Andrew
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (01) : S58 - S58
  • [29] Dietary cholesterol in alcohol-associated liver disease
    Jia, Lin
    IMMUNOMETABOLISM, 2023, 5 (02) : E00026
  • [30] Rifaximin-α in alcohol-associated liver disease
    Xie, Chencheng
    Singal, Ashwani K.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (06): : 495 - 497